Data from Novel Matrix Metalloproteinase Inhibitor [<sup>18</sup>F]Marimastat-Aryltrifluoroborate as a Probe for <i>In vivo</i> Positron Emission Tomography Imaging in Cancer

Matrix metalloproteinases (MMP), strongly associated pathogenic markers of cancer, have undergone extensive drug development programs. Marimastat, a noncovalent MMP inhibitor, was conjugated with FITC to label cellular metalloproteinase cancer targets in MDA-MB-231 cells in vitro. Punctate localization of active transmembrane MMP14 was observed. For molecular-targeted positron emission tomography imaging of syngeneic 67NR murine mammary carcinoma in vivo, marimastat was ¹⁸F-labeled using a shelf-stable arylboronic ester conjugate as a captor for aqueous [¹⁸F]fluoride in a novel, rapid one-step reaction at ambient temperature. [¹⁸F]Marimastat-aryltrifluoroborate localized to the tumors, with labeling being blocked in control animals first loaded with >10-fold excess unlabeled marimastat. The labeled drug cleared primarily via the hepatobiliary and gastrointestinal tract, with multiple animals imaged in independent experiments, confirming the ease of this new labeling strategy. Cancer Res; 70(19); 7562–9. ©2010 AACR.